Products for Research Use Only
RegisterLogin

Hexamethylene bisacetamide

CAT: 0804-HY-124284-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-124284-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].
CAS Number
3073-59-4
Product Name Alternative
HMBA
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Akt; Apoptosis; Bcl-2 Family; Epigenetic Reader Domain; MDM-2/p53; NF-κB; Notch; p38 MAPK
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; MAPK/ERK Pathway; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/hexamethylene-bisacetamide.html
Purity
99.56
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 100 mg/mL (ultrasonic)
Smiles
CC(NCCCCCCNC(C)=O)=O
Molecular Formula
C10H20N2O2
Molecular Weight
200.28
Precautions
H302, H315, H319, H335
References & Citations
[1]Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84 (5) :831-8.|[2]Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7 (23) :3759-67.|[3]Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32 (5) :791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ |[4]Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76 (8) :2376-83.|[5]Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15 (12) :e18024.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-128067-015- (N, N-Hexamethylene) -amiloride
HY-128067R-015- (N, N-Hexamethylene) -amiloride (Standard)
HY-141230-01Hexaethylene glycol
HY-151651-01Hexaethylene glycol phosphoramidite
HY-W042625-01Hexaethylene glycol monomethyl ether
HY-W250198-01Hexaethylene glycol monododecyl ether
HY-134746-01Hexaethylene glycol dimethyl ether
HY-W286073Hexaethylene glycol decyl ether
HY-29504-01Hexaethylene glycol monotridecyl ether
HY-W250195-01Hexaethylene glycol monotetradecyl ether

Alternative Products

CatalogName
MBS3603979-01Hexamethylene bisacetamide
FY13208HEXIM2 Antibody / Hexamethylene bisacetamide-inducible protein 2
MBS601303-01HMBA Inducible 1 (Hexamethylene Bisacetamide Inducible Protein 1, HEXIM1, CLP1, EDG1, FLJ13562, MAQ1)
H6185-02HMBA Inducible (Hexamethylene Bisacetamide Inducible Protein, HIS1, Likely Ortholog of Mouse Cardiac Lineage Protein 1) discontinued
MBS5791291Pentamethylene bisacetamide
E08000Ethylene bisacetamide 95%
17913-72Hexamethylene Glycol
sc-252883Hexamethylene diisocyanate
OR924777Hexamethylene oxide
M19324-01Hexamethylene amiloride

Popular Products